Clinical feature No. DAPK1 unmethylated % DAPK1 Methylated % P value
Patients 200 109 54.5 91 45.5% <0.0001
Males 128 62 48.4% 66 51.5% 0.02
Female 72 47 65.2% 25 34.7%
CP-CML 81 57 70.3% 24 29.6% <0.0001
AP-CML 54 28 51.8% 26 48.1%
BC-CML 65 24 36.9% 41 63.07%
A2b2 59 35 59.3% 24 40.6% 0.5
A2B3 124 64 51.6% 60 48.3%
A2b2/ A2b3 17 10 58.8% 7 41.1%
Imatinib 200 109 54.5% 91 45.5%  
Age >45 71 39 54.9% 32 45.07% 0.9
Age <45 129 70 54.2% 59 45.7%
MMR 50 31 62% 19 38% 0.4
No MR 150 78 52% 72 48%
MHR 30 20 66.6% 10 33.3% 0.02
Minor HR 46 29 63.04 17 36.9%
Loss HR 124 60 48.3% 64 51.6%
Thrombocytopenia 100 52 52 48 48% 0.5
Table 4: Association of DAPK1 aberrant methylation with clinicopathological parameters.